Konishi R, Tanaka R, Inoue S, Ichimura Y, et al. Evaluation of apremilast, an oral phosphodiesterase 4 inhibitor, for refractory cutaneous dermatomyositis: A phase 1b clinical trial. J Dermatol 2021 Oct 3. doi: 10.1111/1346-8138.16179.
PMID: 34605053